| Table of Contents | ||
|---|---|---|
|
A11.1 Purpose
This document provides guidance for indicating that patient consent has been provided for a diagnostic services report to be uploaded to a shared eHealth repository (i.e. Personally Controlled Electronic Health Record System, PCEHR) using a HL7™ V2 message.
A11.2 Introduction
This Technical Specification constrains the usage of order and response messages and standardises terminology in some areas to allow a specific use case to be implemented using the existing Australian and International HL7™ V2 standards.
It introduces no new message types to those that have already been defined in AS 4700.2-2012.
The methodology used for the HL7™ V2 Indication of Consent message is the same as the method used for requesting historical results described in HB 5530-2013 A guide to accessing historical reports from pathology providers.
A11.3 The Indication of Consent Message
A11.3.1 General
Although providing consent for a report to be transmitted to a shared repository such as the PCEHR, is a new activity, delivering the indication message from the patient’s healthcare provider to the diagnostics provider can be accommodated with existing messaging channels. When the healthcare provider indicating the consent uses a standard order message (ORM^O01) the diagnostics provider may respond asynchronously with an ORR^O02. The diagnostics provider can then transmit the diagnostics results report to the shared repository.
In the context of an indication of consent of a diagnostics result report, the function of this message is to communicate that consent has been withdrawn or not withdrawn to a diagnostics service provider for the report to be sent to a shared repository. The ORM message is initiated by a patient’s health care provider at either the time or request for the investigation or at the time of review.
A11.3.2 ORM^O01 trigger event
The trigger event in the ORM^O01 is represented as with the ORC-1 value being either “SC” (Status Change) or “NW” (New Order).
With the use of the ORM^O01 message, it is important that diagnostic providers are able to distinguish an authorisation for a result report to be posted to a repository e.g. PCEHR, from a pathology/laboratory new test order. This should be readily differentiated by the contents of ORC-1 where the authorisation will contain “SC” and a new diagnostics request will contain “NW”.
The current HL7™ V2 standards in Australia allows for all of the order message requirements listed in HL7™ Sections 4.2 to 4.6 to be satisfied when they are needed.
Table 2 describes the structure of the diagnostics order message (ORM). Refer to HL7™ V2.4, section 4.4.1.
This message profile can be used in two modes. One as a part of a new order or when consent is being revised at the time or reviewing a report.
TABLE 1
DIAGNOSTICS ORDER (ORM^O01) MESSAGE STRUCTURE
| ORM^O01^ORM_O01 | Usage | Segment Description | HL7™ V2.4, Chapter |
|---|---|---|---|
MSH | R | Message Header | 2 |
PID | R | Patient Identification | 3 |
[PV1] | RE | Patient Visit | 3 |
[IN1] | RE | Insurance | 6 |
[GT1] | RE | Guarantor | 6 |
{ |
|
|
|
ORC | R | Common Order | 4 |
[ |
|
|
|
OBR | RE | Observation Request | 4 |
[{OBX}] | RE | Observation/Result | 7 |
] |
|
|
|
} |
|
|
|
A11.3.3 Indication of Consent and posting to the PCEHR
The communication of consent status provides the diagnostic services provider guidance regarding the posting of a report to the PCEHR and will depend on the contents of OBX-3 when the content is “|728301000168101^Patient consent to upload healthcare document^SCT|” and OBX-5 is set to “|728321000168105^Patient consent not withdrawn^SCT|” then the report has the appropriate patient consent to be uploaded to the shared repository.
If no indication of consent message is sent, standing consent is assumed and the diagnostic report should be sent to the PCEHR provided the patient has not withdrawn consent through other channels and the patient has a PCEHR.
In order to avoid storing information in the PCEHR system for consumers who are not registered for a PCEHR, systems must first check whether the consumer has a PCEHR. This can be achieved by calling the doesPCEHRExist function on the national PCEHR Service through the B2B Gateway or through the use of the message described in this document.
The response to a doesPCEHRexist query will be “Yes” in the following cases:
- The Consumer has a PCEHR and they have elected to automatically notify healthcare providers that it exists (i.e. they have not dissented to the “advertise’ function’).
- The Consumer has a PCEHR and has elected not to automatically notify healthcare providers that it exists but the requesting healthcare provider/diagnostic service provider is on their access list.
Diagnostic Service reports may be sent to the PCEHR where the response to the doesPCEHRexist query is “Yes”.
The response to a doesPCEHRexist query will be “No” in the following cases:
- The Consumer does not have a PCEHR.
- The Consumer has a PCEHR however they have elected not to automatically notify healthcare providers that it exists and the requesting healthcare provider/diagnostic service provider is not on the access list.
Diagnostic Service reports are not to be sent to the PCEHR where the response to the doesPCEHRexist query is “No” unless the consumer has confirmed to the Diagnostic Service Provider that they have a PCEHR record and they would like the report sent to the PCEHR. This specification also includes the ability for a healthcare provider to indicate to another that a PCEHR record exists. In the event when a healthcare provider has indicated to the diagnostic service provider that a PCEHR exists it is not required to do the doesPCEHRexist query as the record may be hidden.
A11.4 Indication of Consent message criteria mapping
Table 2 outlines the fields used for specific selection criteria.
...
MSH|^~\&|SUPER-LIS^2.16.840.1.113883.19.1^ISO|NEHTAPATH^4321^AUSNATA|Rhubarb-EMR^2.16.840.1.113883.19.4.2^ISO|NEHTAHOSP^2.16.840.1.113883.19.5^ISO|201504111025+1000||ORU^R01^ORU_R01|P0000051504102331070|P|2.4|||AL|NE|AUS|8859/1
PID|1||2142363^^^NEHTAHOSP^MR~61405230941^^^AUSHIC^MC~WA123456B^^^AUSDVA^DVG~8003608833357361^^^AUSHIC^NI||PatientSurnameOne^FirstnameOne^MiddleNameOne^SufixOne^PrefixOne^^L~PatientSurnameTwo^FirstnameTwo^MiddleNameTwo^SufixTwo^PrefixTwo^^M||194506241031|M|||Unit 1^111 Nehta Street^Brisbane^^4000^AUS^H~Unit 2^222 NehtaTwo Street^Brisbane^^4000^AUS^B||^PRN^PH^^^^93235615|^WPN^CP^^^^0414778341
PV1|1|O|Ward1^RoomE8^Bed10^NEHTAHOSP&2.16.840.1.113883.19.5&ISO||||ABCB^DrASurname^DrAttending^^^^Dr^^SUPER-LIS~123456^DrASurname^DrAttending^^^^Dr^^NEHTAHOSP~2304227F^DrASurname^DrAttending^^^^Dr^^AUSHICPR|HIJK^DrASurname^DrReferring^^^^Dr^^SUPER-LIS~858595^DrASurname^DrReferring^^^^Dr^^NEHTAHOSP~2929016F^DrASurname^DrReferring^^^^Dr^^AUSHICPR
ORC|RE|112233^RhubarbOrders^2.16.840.1.113883.19.4.1.5^ISO|15P000005-123456^SUPER-LIS^2.16.840.1.113883.19.1.2^ISO|44556677^RhubarbOrdersGroupID^2.16.840.1.113883.19.4.1.4^ISO|CM||||201504100800+1000|||DFTR^DrBSurname^DrOrdering^^^^Dr^^SUPER-LIS~958678^DrBSurname^DrOrdering^^^^Dr^^NEHTAHOSP~4322581B^DrBSurname^DrOrdering^^^^Dr^^AUSHICPR||^WPN^PH^^^^0893412041|201504100730+1000
OBR|1|112233^RhubarbOrders^2.16.840.1.113883.19.4.1.5^ISO|15P000005-123456^SUPER-LIS^2.16.840.1.113883.19.1.2^ISO|FBE^Full Blood Count^SUPER-LIS^26604007^Complete blood count^SCT|||201504100930+1000||||||Patient has a history of severe gout caused by rhubarb.|201504101100+1000||DFTR^DrBSurname^DrOrdering^^^^Dr^^SUPER-LIS~958678^DrBSurname^DrOrdering^^^^Dr^^NEHTAHOSP~4322581B^DrBSurname^DrOrdering^^^^Dr^^AUSHICPR~8003600000000000^DrBSurname^DrOrdering^^^^Dr^^AUSHIC^^^^^NPI|^WPN^PH^^^^0893412041|||CP=N,DR=4322581B||201504101115+1000||HM|F||^^^201504100800+1000^^RT|2304227F^DrCopyASurname^DrCopyToA^^^^Dr^^AUSHICPR~0813266H^DrCopyBSurname^DrCopyToB^^^^Dr^^AUSHICPR~4628361B^DrCopyCSurname^DrCopyToC^^^^Dr^^AUSHICPR||||DRPRIH&DrSurname&PrincipalResultInterpreterHaem&&&DR&&&SUPER-LIS
OBX|1|NM|718-7^Hemoglobin^LN^HB^Haemoglobin^NEHTAPATH||145|g/L^^ISO+|130-180||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|2|NM|789-8^Erythrocytes^LN^RCC^Red Cell Count^NEHTAPATH||5.30|x10\S\12/L^^ISO+|4.50-6.50||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|3|NM|4544-3^Hematocrit^LN^HCT^HCT^NEHTAPATH||0.43|L/L^^ISO+|0.40-0.54||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|4|NM|MCV^MCV^NEHTAPATH||81|fL^^ISO+|80-96||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|5|NM|MCH^MCH^NEHTAPATH||27.4|pg^^ISO+|24.0-32.0||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|6|NM|MCHC^MCHC^NEHTAPATH||338|g/L^^ISO+|320-360||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|7|NM|PLAT^Platelet^NEHTAPATH||198|x10\S\9/L^^ISO+|150-400||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|8|NM|WCC^White Cell Count^NEHTAPATH||12.1|x10\S\9/L^^ISO+|4.0-11.0|H|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|9|NM|NEUTS^Neutrophils^NEHTAPATH||9.3|x10\S\9/L^^ISO+|2.0-7.5|H|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|10|NM|LYMPHOS^Lymphocytes^NEHTAPATH||2.1|x10\S\9/L^^ISO+|1.0-4.0||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|11|NM|MONOS^Monocytes^NEHTAPATH||0.7|x10\S\9/L^^ISO+|0.1-0.8||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|12|NM|EOS^Eosinophils^NEHTAPATH||0.0|x10\S\9/L^^ISO+|0.0-0.4||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|13|NM|BASOS^Basophils^NEHTAPATH||0.0|x10\S\9/L^^ISO+|0.0-0.2||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|14|FT|TXT^Display format in text^AUSPDI||\.br\------------------------- Haematology Report ---------------------------------\.br\\.br\CUMULATIVE REPORT\.br\Req No: P000001 P000002 P000003 P000004 P000005\.br\ Date: 29/06/13 30/06/13 01/07/13 16/07/13 10/04/15\.br\ Time: 07:37 08:23 08:20 19:20 23:30 Units Ref Range\.br\------------------------------------------------------------------------------\.br\BLOOD COUNT\.br\Hb 138 141 139 135 145 g/L 130-180\.br\WCC 7.9 7.5 7.5 9.5 12.1H x10\S\9/L 4.0-11.0\.br\Plat 280 299 272 186 198 x10\S\9/L 150-400\.br\MCV 87 88 86 86 81 fL 80-96\.br\RCC 4.87 5.02 4.97 4.79 5.30 x10\S\12/L 4.50-6.50\.br\HCT 0.42 0.44 0.43 0.41 0.43 L/L 0.40-0.54\.br\MCH 28.3 28.1 28.0 28.2 27.4 pg 24.0-32.0\.br\MCHC 327 320 326 328 338 g/L 320-360\.br\RDW 13.8 13.9 14.0 14.3H 15.5H % 11.0-14.0\.br\MPV 10.7 10.8H 10.7 11.0H 11.2H fL 6.4-10.7\.br\Differential\.br\Neut 3.9 3.6 3.7 4.6 9.3H x10\S\9/L 2.0-7.5\.br\Lymph 2.9 2.9 2.7 3.6 2.1 x10\S\9/L 1.0-4.0\.br\Mono 0.7 0.5 0.6 0.7 0.7 x10\S\9/L 0.1-0.8\.br\Eos 0.5H 0.4 0.4 0.6H 0.0 x10\S\9/L 0.0-0.4\.br\Baso 0.0 0.0 0.0 0.0 0.0 x10\S\9/L 0.0-0.2\.br\\.br\------------------------- Microbiology Report ---------------------------------\.br\\.br\SPECIMEN Lab No : P000005 \.br\Specimen Type : Urine \.br\ \.br\MICROSCOPY \.br\Leucocyte Range >500 x10E6/L (<10) \.br\Erythrocyte Range >500 x10E6/L (<10) \.br\Epithelial Cells not seen \.br\Bacteria moderate \.br\ \.br\Antibacterial Activity Not Detected \.br\ \.br\CULTURE \.br\ \.br\1. Enterobacter cloacae >=10E8 cfu/L \.br\2. Escherichia coli O112 150 \.br\ \.br\SENSITIVITIES: 1 \.br\ \.br\Amox/Clavulanate R \.br\Gentamicin S \.br\Meropenem S \.br\Nitrofurantoin R \.br\Norfloxacin S \.br\Trimethoprim S \.br\ \.br\COMMENT \.br\Organism 1 \.br\ESCAPPM organisms include Enterobacter, Serratia, Citrobacter, \.br\Aeromonas, Hafnia, Providencia and Morganella. \.br\These bacteria possess inducible beta-lactamases and resistance \.br\may arise during treatment with the Penicillins (Amoxycillin, \.br\Augmentin, Timentin, Piperacillin and Tazobactam) and the \.br\Cephalosporins (Cephalothin, Cephazolin, Ceftriaxone, Cefotaxime, \.br\Ceftazidime and Aztreonam). \.br\ \.br\INTERPRETATION OF MIDSTREAM/CLEAN-CATCH URINE CULTURE RESULTS \.br\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\ \.br\A Bacterial Count of >=10e7 cfu/L is consistent with Urinary Tract \.br\Infection. There are no such quantitative ISOelines for Candida. \.br\A leucocyte count of >=10x10e6/L is abnormal. \.br\Epithelial cells, if present, may reflect urogenital contamination. \.br\An organism count >=10e7 cfu/L, in the absence of a raised leucocyte \.br\count, may reflect overflow from a bacteraemia or lack of specimen \.br\refrigeration with bacterial overgrowth prior to culture. \.br\ \.br\INTERPRETATION OF INDWELLING CATHETER URINE CULTURE RESULTS \.br\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\ \.br\If this urine was collected via an indwelling urinary catheter (IDC) \.br\results are consistent with either IDC colonisation or infection. \.br\Antibiotic therapy with the catheter in situ is seldom successful. \.br\IDC removal, if possible, or replacement is suggested. \.br\Treatment should be ISOed by clinical signs such as fever, pain and \.br\raised peripheral leucocyte count etc.\.br\|||A|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
ORC|RE|112234^RhubarbOrders^2.16.840.1.113883.19.4.1.5^ISO|15P000005-123457^SUPER-LIS^2.16.840.1.113883.19.1.2^ISO|44556677^RhubarbOrdersGroupID^2.16.840.1.113883.19.4.1.4^ISO|CM||||201504100800+1000|||DFTR^DrBSurname^DrOrdering^^^^Dr^^SUPER-LIS~958678^DrBSurname^DrOrdering^^^^Dr^^NEHTAHOSP~4322581B^DrBSurname^DrOrdering^^^^Dr^^AUSHICPR||^WPN^PH^^^^0893412041|201504100730+1000
OBR|2|112234^RhubarbOrders^2.16.840.1.113883.19.4.1.5^ISO|15P000005-123457^SUPER-LIS^2.16.840.1.113883.19.1.2^ISO|UrineMCS^URINE MC\T\S^SUPER-LIS^401324008^Urinary microscopy, culture and sensitivities^SCT|||201504100930+1000||||||Patient has a history of severe gout caused by rhubarb.|201504101100+1000||DFTR^DrBSurname^DrOrdering^^^^Dr^^SUPER-LIS~958678^DrBSurname^DrOrdering^^^^Dr^^NEHTAHOSP~4322581B^DrBSurname^DrOrdering^^^^Dr^^AUSHICPR~8003600000000000^DrBSurname^DrOrdering^^^^Dr^^AUSHIC^^^^^NPI|^WPN^PH^^^^0893412041|||CP=N,DR=4322581B||201504111020+1000||HM|F||^^^201504100800+1000^^RT|2304227F^DrCopyASurname^DrCopyToA^^^^Dr^^AUSHICPR~0813266H^DrCopyBSurname^DrCopyToB^^^^Dr^^AUSHICPR~4628361B^DrCopyCSurname^DrCopyToC^^^^Dr^^AUSHICPR||||DRPRIM&DrSurname&PrincipalResultInterpreterMicro&&&DR&&&SUPER-LIS
OBX|1|ST|53903-1^Specimen^LN^Spec^Specimen^NEHTAPATH||Urine||||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|2|ST|Lab number^LabNo^LN^LabNo^LabNo^NEHTAPATH||M000001||||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|3|SN|30405-5^Leucocyte Range^LN^Leuc Range^Leucocyte Range^NEHTAPATH||>^500|x10E6/L|<10|H|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|4|SN|30391-7^Erythrocyte Range^LN^Ery Range^Erythrocyte Range^NEHTAPATH||>^500|x10E6/L|<10|H|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|5|ST|20453-7^Epithelial Cells^LN^Epith^Epithelial Cells^NEHTAPATH||not seen||||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|6|ST|50221-1^Bacteria^LN^Bac^Bacteria^NEHTAPATH||moderate||||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|7|ST|30910-4^Antibacterial Activity^LN^ABS^Antibacterial Activity^NEHTAPATH||Not Detected||||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|8|FT|8262-8^AutoComment^LN^UAutoCom^AutoComment^NEHTAPATH||\.br\Organism 1\.br\ESCAPPM organisms include Enterobacter, Serratia, Citrobacter,\.br\Aeromonas, Hafnia, Providencia and Morganella.\.br\These bacteria possess inducible beta-lactamases and resistance\.br\may arise during treatment with the Penicillins (Amoxycillin,\.br\Augmentin, Timentin, Piperacillin and Tazobactam) and the\.br\Cephalosporins (Cephalothin, Cephazolin, Ceftriaxone, Cefotaxime,\.br\Ceftazidime and Aztreonam).\.br\\.br\INTERPRETATION OF MIDSTREAM/CLEAN-CATCH URINE CULTURE RESULTS\.br\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\.br\A Bacterial Count of >=10e7 cfu/L is consistent with Urinary Tract\.br\Infection. There are no such quantitative ISOelines for Candida.\.br\A leucocyte count of >=10x10e6/L is abnormal.\.br\Epithelial cells, if present, may reflect urogenital contamination.\.br\An organism count >=10e7 cfu/L, in the absence of a raised leucocyte\.br\count, may reflect overflow from a bacteraemia or lack of specimen\.br\refrigeration with bacterial overgrowth prior to culture.\.br\\.br\INTERPRETATION OF INDWELLING CATHETER URINE CULTURE RESULTS\.br\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\.br\If this urine was collected via an indwelling urinary catheter (IDC)\.br\results are consistent with either IDC colonisation or infection.\.br\Antibiotic therapy with the catheter in situ is seldom successful.\.br\IDC removal, if possible, or replacement is suggested.\.br\Treatment should be ISOed by clinical signs such as fever, pain and\.br\raised peripheral leucocyte count etc.\.br\\.br\||||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|9|ST|11475-1^Culture^LN|1|Enterobacter cloacae||||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|10|ST|699-9^Culture Count^LN|1|>=10E8 cfu/L||||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|11|ST|11475-1^Culture^LN|2|Escherichia coli O112||||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|12|ST|699-9^Culture Count^LN|2|150||||||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|13|ST|18862-3^Amox/Clavulanate^LN^AMC^Amox/Clavulanate^NEHTAPATH|1|R|||R|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|14|ST|18928-2^Gentamicin^LN^GEN^Gentamicin^NEHTAPATH|1|S|||S|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|15|ST|18997-7^Trimethoprim^LN^TRI^Trimethoprim^NEHTAPATH|1|S|||S|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|16|ST|18955-5^Nitrofurantoin^LN^NIT^Nitrofurantoin^NEHTAPATH|1|R|||R|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|17|ST|18956-3^Norfloxacin^LN^NOR^Norfloxacin^NEHTAPATH|1|S|||S|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|18|ST|18943-1^Meropenem^LN^MER^Meropenem^NEHTAPATH|1|S|||S|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
OBX|14|FT|TXT^Display format in text^AUSPDI^UrineMCS^URINE MC\T\S^NEHTAPATH||\.br\------------------------- Haematology Report ---------------------------------\.br\\.br\CUMULATIVE REPORT\.br\Req No: P000001 P000002 P000003 P000004 P000005\.br\ Date: 29/06/13 30/06/13 01/07/13 16/07/13 10/04/15\.br\ Time: 07:37 08:23 08:20 19:20 23:30 Units Ref Range\.br\------------------------------------------------------------------------------\.br\BLOOD COUNT\.br\Hb 138 141 139 135 145 g/L 130-180\.br\WCC 7.9 7.5 7.5 9.5 12.1H x10\S\9/L 4.0-11.0\.br\Plat 280 299 272 186 198 x10\S\9/L 150-400\.br\MCV 87 88 86 86 81 fL 80-96\.br\RCC 4.87 5.02 4.97 4.79 5.30 x10\S\12/L 4.50-6.50\.br\HCT 0.42 0.44 0.43 0.41 0.43 L/L 0.40-0.54\.br\MCH 28.3 28.1 28.0 28.2 27.4 pg 24.0-32.0\.br\MCHC 327 320 326 328 338 g/L 320-360\.br\RDW 13.8 13.9 14.0 14.3H 15.5H % 11.0-14.0\.br\MPV 10.7 10.8H 10.7 11.0H 11.2H fL 6.4-10.7\.br\Differential\.br\Neut 3.9 3.6 3.7 4.6 9.3H x10\S\9/L 2.0-7.5\.br\Lymph 2.9 2.9 2.7 3.6 2.1 x10\S\9/L 1.0-4.0\.br\Mono 0.7 0.5 0.6 0.7 0.7 x10\S\9/L 0.1-0.8\.br\Eos 0.5H 0.4 0.4 0.6H 0.0 x10\S\9/L 0.0-0.4\.br\Baso 0.0 0.0 0.0 0.0 0.0 x10\S\9/L 0.0-0.2\.br\\.br\------------------------- Microbiology Report ---------------------------------\.br\\.br\SPECIMEN Lab No : P000005 \.br\Specimen Type : Urine \.br\ \.br\MICROSCOPY \.br\Leucocyte Range >500 x10E6/L (<10) \.br\Erythrocyte Range >500 x10E6/L (<10) \.br\Epithelial Cells not seen \.br\Bacteria moderate \.br\ \.br\Antibacterial Activity Not Detected \.br\ \.br\CULTURE \.br\ \.br\1. Enterobacter cloacae >=10E8 cfu/L \.br\2. Escherichia coli O112 150 \.br\ \.br\SENSITIVITIES: 1 \.br\ \.br\Amox/Clavulanate R \.br\Gentamicin S \.br\Meropenem S \.br\Nitrofurantoin R \.br\Norfloxacin S \.br\Trimethoprim S \.br\ \.br\COMMENT \.br\Organism 1 \.br\ESCAPPM organisms include Enterobacter, Serratia, Citrobacter, \.br\Aeromonas, Hafnia, Providencia and Morganella. \.br\These bacteria possess inducible beta-lactamases and resistance \.br\may arise during treatment with the Penicillins (Amoxycillin, \.br\Augmentin, Timentin, Piperacillin and Tazobactam) and the \.br\Cephalosporins (Cephalothin, Cephazolin, Ceftriaxone, Cefotaxime, \.br\Ceftazidime and Aztreonam). \.br\ \.br\INTERPRETATION OF MIDSTREAM/CLEAN-CATCH URINE CULTURE RESULTS \.br\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\ \.br\A Bacterial Count of >=10e7 cfu/L is consistent with Urinary Tract \.br\Infection. There are no such quantitative ISOelines for Candida. \.br\A leucocyte count of >=10x10e6/L is abnormal. \.br\Epithelial cells, if present, may reflect urogenital contamination. \.br\An organism count >=10e7 cfu/L, in the absence of a raised leucocyte \.br\count, may reflect overflow from a bacteraemia or lack of specimen \.br\refrigeration with bacterial overgrowth prior to culture. \.br\ \.br\INTERPRETATION OF INDWELLING CATHETER URINE CULTURE RESULTS \.br\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\\R\ \.br\If this urine was collected via an indwelling urinary catheter (IDC) \.br\results are consistent with either IDC colonisation or infection. \.br\Antibiotic therapy with the catheter in situ is seldom successful. \.br\IDC removal, if possible, or replacement is suggested. \.br\Treatment should be ISOed by clinical signs such as fever, pain and \.br\raised peripheral leucocyte count etc.\.br\|||A|||F|||201504100930+1000|""|RO56^SurnameResponsibleObserver^Givenname^^^^^^SUPER-LIS
Message 4: Indication of Consent Message
MSH|^~\&|Rhubarb-CPOE^2.16.840.1.113883.19.4.1^ISO|NEHTAHOSP^2.16.840.1.113883.19.5^ISO|SUPER-LIS^2.16.840.1.113883.19.1^ISO|NEHTAPATH^4321^AUSNATA|201504120933+1000||ORM^O01^ORM_O01|P5560801311070009864|P|2.4|||AL|NE|AUS|8859/1
PID|1||2142363^^^NEHTAHOSP^MR~61405230941^^^AUSHIC^MC~WA123456B^^^AUSDVA^DVG~2.16.840.1.113883.19.100^^^AUSHIC^NI||PatientSurnameOne^FirstnameOne^MiddleNameOne^SufixOne^PrefixOne^^L~PatientSurnameTwo^FirstnameTwo^MiddleNameTwo^SufixTwo^PrefixTwo^^M||194506241031|M|||Unit 1^111 Nehta Street^Brisbane^^4000^AUS^H~Unit 2^222 NehtaTwo Street^Brisbane^^4000^AUS^B||^PRN^PH^^^^93235615|^WPN^CP^^^^0414778341
PV1|1|O|Ward1^RoomE8^Bed10^NEHTAHOSP&2.16.840.1.113883.19.5&ISO||||ABCB^DrASurname^DrAttending^^^^Dr^^SUPER-LIS~123456^DrASurname^DrAttending^^^^Dr^^NEHTAHOSP~2304227F^DrASurname^DrAttending^^^^Dr^^AUSHICPR|HIJK^DrASurname^DrReferring^^^^Dr^^SUPER-LIS~858595^DrASurname^DrReferring^^^^Dr^^NEHTAHOSP~2929016F^DrASurname^DrReferring^^^^Dr^^AUSHICPR
ORC|SC|112233^RhubarbOrders^2.16.840.1.113883.19.4.1.5^ISO|15P000005-123456^SUPER-LIS^2.16.840.1.113883.19.1.2^ISO|44556677^RhubarbOrdersGroupID^2.16.840.1.113883.19.4.1.4^ISO||||||||DFTR^DrBSurname^DrOrdering^^^^Dr^^SUPER-LIS~958678^DrASurname^DrOrdering^^^^Dr^^NEHTAHOSP~4322581B^DrBSurname^DrOrdering^^^^Dr^^AUSHICPR|||
OBR|1|112233^RhubarbOrders^2.16.840.1.113883.19.4.1.5^ISO|15P000005-123456^SUPER-LIS^2.16.840.1.113883.19.1.2^ISO|FBE^Full Blood Count^SUPER-LIS^26604007^Complete blood count^SCT|||201504100930+1000|20131106233000+0800|||||Patient has a history of severe gout caused by rhubarb.|201504101100+1000||DFTR^DrBSurname^DrOrdering^^^^Dr^^SUPER-LIS~958678^DrASurname^DrOrdering^^^^Dr^^NEHTAHOSP~4322581B^DrBSurname^DrOrdering^^^^Dr^^AUSHICPR~8003600000000000^DrBSurname^DrOrdering^^^^Dr^^AUSHIC^^^^^NPI|^WPN^PH^^^^0893412041|||CP=N,DR=4322581B||201504101115+1000||HM|F||^^^201504100800+1000^^RT|2304227F^DrCopyASurname^DrCopyToA^^^^Dr^^AUSHICPR~0813266H^DrCopyBSurname^DrCopyToB^^^^Dr^^AUSHICPR~4628361B^DrCopyCSurname^DrCopyToC^^^^Dr^^AUSHICPR||||DRPRIH&DrSurname&PrincipalResultInterpreterHaem&&&DR&&&SUPER-LIS
OBX|1|RP|60572-5^^LN^ENTRY^^EN 13606|1|CEN-Repository-Consent.v1^Repository Consent&99A-9B6A27841D4552AB&L^TEXT^Octet-stream||||||O
OBX|2|CE|728301000168101^Patient consent to upload healthcare document^SCT|1.1|728321000168105^Patient consent not withdrawn^SCT||||||O
OBX|3|CE|728211000168106^eHealth record ownership^SCT|1.2|728221000168104^Patient has eHealth record^SCT||||||O
OBX|4|CE|74835-2^Health Data Repository (Identifier)^LN|1.3|8003640002000050^MyEHR Health Repository^GSO||||||O
ORC|SC|112234^RhubarbOrders^2.16.840.1.113883.19.4.1.5^ISO|15P000005-123457^SUPER-LIS^2.16.840.1.113883.19.1.2^ISO|44556677^RhubarbOrdersGroupID^2.16.840.1.113883.19.4.1.4^ISO||||||||DFTR^DrBSurname^DrOrdering^^^^Dr^^SUPER-LIS~958678^DrASurname^DrOrdering^^^^Dr^^NEHTAHOSP~4322581B^DrBSurname^DrOrdering^^^^Dr^^AUSHICPR|||
OBR|2|112234^RhubarbOrders^2.16.840.1.113883.19.4.1.5^ISO|15P000005-123457^SUPER-LIS^2.16.840.1.113883.19.1.2^ISO|UrineMCS^URINE MC\T\S^SUPER-LIS^401324008^Urinary microscopy, culture and sensitivities^SCT|||201504100930+1000|20131106233000+0800|||||Patient has a history of severe gout caused by rhubarb.|201504101100+1000||DFTR^DrBSurname^DrOrdering^^^^Dr^^SUPER-LIS~958678^DrASurname^DrOrdering^^^^Dr^^NEHTAHOSP~4322581B^DrBSurname^DrOrdering^^^^Dr^^AUSHICPR~8003600000000000^DrBSurname^DrOrdering^^^^Dr^^AUSHIC^^^^^NPI|^WPN^PH^^^^0893412041|||CP=N,DR=4322581B||201504111020+1000||HM|F||^^^201504100800+1000^^RT|2304227F^DrCopyASurname^DrCopyToA^^^^Dr^^AUSHICPR~0813266H^DrCopyBSurname^DrCopyToB^^^^Dr^^AUSHICPR~4628361B^DrCopyCSurname^DrCopyToC^^^^Dr^^AUSHICPR||||DRPRIM&DrSurname&PrincipalResultInterpreterMicro&&&DR&&&SUPER-LIS
OBX|1|RP|60572-5^^LN^ENTRY^^EN 13606|1|CEN-Repository-Consent.v1^Repository Consent&99A-9B6A27841D4552AB&L^TEXT^Octet-stream||||||O
OBX|2|CE|728301000168101^Patient consent to upload healthcare document^SCT|1.1|728321000168105^Patient consent not withdrawn^SCT||||||O
OBX|3|CE|728211000168106^eHealth record ownership^SCT|1.2|728221000168104^Patient has eHealth record^SCT||||||O
OBX|4|CE|74835-2^Health Data Repository (Identifier)^LN|1.3|8003640002000050^MyEHR Health Repository^GSO||||||O
A11.6 References
AS 4700.2-2012 Implementation of Health Level Seven (HL7™) Version 2.4 - Pathology and diagnostic imaging (diagnostics)
...
HB 234-2012 Healthcare identifier HL7 implementation guide
A11.7 Acknowledgements
The following individuals were consulted on the development of the indication of consent guidance.
...